ALBUMIN AND ITS ROLE IN UROLITHIASIS
Urolithiasis is a multifactorial disease with an incidence rate of more than one million cases reported annually in India. Various forms of the calculus have been reported to have 90-95% inorganic and 5% organic matter. Out of the major proteins that comprise this organic component of the matrix, albumin, and uromodulin are found to be the most abundant. Albumin is also the most abundant protein in the human blood serum where it plays the role of a transporter of hormones, fatty acids, and other compounds. The increased concentrations of albumin may significantly affect a patientâ€™s susceptibility to kidney stone formation. The study of the role of albumin in urolithiasis could give us useful insights on its potential role in this disease and may add to the therapeutic repertoire of albumin.
2. Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC. Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int 2003;63(5):1817-23.
3. Soucie JM, Thun MJ, Coates RJ, McClellan W, Austin H. Demographic and geographic variability of kidney stones in the United States. Kidney Int 1994;46(3):893-9.
4. Aduayi OS, Famurewa OC. Cystolithiasis with coexisting nephrolithiasis :A radiodiagnostic discovery in an adult Nigerian male with lower urinary tract symptoms. J Med Investig Pract 2015;10(1):30-2.
5. Coe FL, Parks JH, Asplin JR. The pathogenesis and treatment of kidney stones. N Engl J Med 1992;327(16):1141-52.
6. Yuvarani T, Manjula K, Gopu P. Growth characterization of calcium hydrogen phosphate dihydrate crystals influenced by costusigneus aqueous extract. Int J Pharm Pharm Sci 2017;9(5):173-8.
7. Perinpam M, Ware EB, Smith JA, Turner ST, Kardia SL, Lieske JC. Effect of demographics on excretion of key urinary factors related to kidney stone risk. Urology 2015;86(4):690-6.
8. Kaneko K, Kobayashi R, Yasuda M, Izumi Y, Yamanobe T, Shimizu T. Comparison of matrix proteins in different types of urinary stone by proteomic analysis using liquid chromatography-tandem mass spectrometry. Int J Urol 2012;19(8):765-72.
9. Palatini P. Glomerular hyperfiltration: A marker of early renal damage in pre-diabetes and pre-hypertension. Nephrol Dial Transplant 2012;27(5):1708-14.
10. Quinlan GJ, Martin GS, Evans TW. Albumin: Biochemical properties and therapeutic potential. Hepatology 2005;41(6):1211-9.
11. Lee E, Eom JE, Jeon KH, Kim TH, Kim E, Jhon GJ, et al. Evaluation of albumin structural modifications through cobalt-albumin binding (CAB) assay. J Pharm Biomed Anal 2014;91:17-23.
12. Fasano M, Curry S, Terreno E, Galliano M, Fanali G, Narciso P, et al. The extraordinary ligand binding properties of human serum albumin. IUBMB Life 2005;57(12):787-96.
13. Kragh-Hansen U, Chuang VT, Otagiri M. Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Biol Pharm Bull 2002;25(6):695-704.
14. Varshney A, Sen P, Ahmad E, Rehan M, Subbarao N, Khan RH. Ligand binding strategies of human serum albumin: How can the cargo be utilized? Chirality 2010;22(1):77-87.
15. Gomella T, Cunningham M, Eyal F, Tuttle D. Neonatology: Management, Procedures, On-Call Problems, Diseases, and Drugs. 6th ed. New York: McGraw-Hill Medical Publishers; 2009. 16. Roche M, Rondeau P, Singh NR, Tarnus E, Bourdon E. The antioxidant properties of serum albumin. FEBS Lett 2008;582(13):1783-7.
17. Wei C, Nguyen SD, Kim MR, Sok DE. Rice albumin N-terminal (Asp-His-His-Gln) prevents against copper ion-catalyzed oxidations. J Agric Food Chem 2007;55(6):2149-54.
18. Halliwell B. Albumin - An important extracellular antioxidant? Biochem Pharmacol 1988;37(4):569-71.
19. Hall J, Guyton A. Pocket Companion to Guyton and Hall Textbook of Medical Physiology. 11th ed. Philadelphia, PA: Elsevier Inc.; 2006.
20. Skillman JJ. The role of albumin and oncotically active fluids in shock. Crit Care Med 1976;4(2):55-61.
21. Tojo A, Kinugasa S. Mechanisms of glomerular albumin filtration and tubular reabsorption. Int J Nephrol 2012;2012:481520.
22. Comper WD, Haraldsson B, Deen WM. Resolved: Normal glomeruli filter nephrotic levels of albumin. J Am Soc Nephrol 2008;19(3):427-32.
23. Terkeltaub RA, Santoro DA, Mandel G, Mandel N. Serum and plasma inhibit neutrophil stimulation by hydroxyapatite crystals. Evidence that serum alpha 2-HS glycoprotein is a potent and specific crystal-bound inhibitor. Arthritis Rheum 1988;31(9):1081-9.
24. Atmani F, Khan SR. Quantification of proteins extracted from calcium oxalate and calcium phosphate crystals induced in vitro in the urine of healthy controls and stone-forming patients. Urol Int 2002;68(1):54-9.
25. Dussol B, Geider S, Lilova A, LÃ©onetti F, Dupuy P, Daudon M, et al. Analysis of the soluble organic matrix of five morphologically different kidney stones. Evidence for a specific role of albumin in the constitution of the stone protein matrix. Urol Res 1995;23(1):45-51.
26. Cerini C, Geider S, Dussol B, Hennequin C, Daudon M, Veesler S, et al. Nucleation of calcium oxalate crystals by albumin: Involvement in the prevention of stone formation. Kidney Int 1999;55(5):1776-86.
27. Liu J, Jiang H, Liu XY. How does bovine serum albumin prevent the formation of kidney stone? A kinetics study. J Phys Chem B 2006;110(18):9085-9.
28. Kavanagh JP, Nishio S, Garside J, Blacklock NJ. Crystallization kinetics of calcium oxalate in fresh, minimally diluted urine: Comparison of recurrent stone formers and healthy controls in a continuous mixed suspension mixed product removal crystallizer. J Urol 1993;149(3):614-7.
29. Robertson WG, Peacock M, Nordin BE. Calcium crystalluria in recurrent renal-stone formers. Lancet 1969;2(7610):21-4.
30. Azoury R, Robertson WG, Garside J. Observations on in vitro and in vivo calcium oxalate crystalluria in primary calcium stone formers and normal subjects. Br J Urol 1987;59(3):211-3.
31. Garnett J, Dieppe P. The effects of serum and human albumin on calcium hydroxyapatite crystal growth. Biochem J 1990;266(3):863-8.
32. Cook AF, Grover PK, Ryall RL. Face-specific binding of prothrombin fragment 1 and human serum albumin to inorganic and urinary calcium oxalate monohydrate crystals. BJU Int 2009;103(3):826-35.
33. Chiangjong W, Thongboonkerd V. A novel assay to evaluate promoting effects of proteins on calcium oxalate crystal invasion through extracellular matrix based on plasminogen/plasmin activity. Talanta 2012;101:240-5.
34. Cupisti A, Meola M, Dâ€™Alessandro C, Bernabini G, Pasquali E, Carpi A, et al. Insulin resistance and low urinary citrate excretion in calcium stone formers. Biomed Pharmacother 2007;61(1):86-90.
35. Kohjimoto Y, Sasaki Y, Iguchi M, Matsumura N, Inagaki T, Hara I. Association of metabolic syndrome traits and severity of kidney stones: Results from a nationwide survey on urolithiasis in Japan. Am J Kidney Dis 2013;61(6):923-9.
36. Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract 2014;2014:943162.
37. DiBianco JM, Jarrett TW, Mufarrij P. Metabolic syndrome and nephrolithiasis risk: Should the medical management of nephrolithiasis include the treatment of metabolic syndrome? Rev Urol 2015;17(3):117-28.
38. Wong YV, Cook P, Somani BK. The association of metabolic syndrome and urolithiasis. Int J Endocrinol 2015;2015:570674.
39. Currie G, Delles C. Proteinuria and its relation to cardiovascular disease. Int J Nephrol Renovasc Dis 2013;7:13-24.
40. Wagner DK, Harris T, Madans JH. Proteinuria as a biomarker: Risk of subsequent morbidity and mortality. Environ Res 1994;66(2):160-72.
41. van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey A, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int 2011;79(12):1341-52.
42. Toto RD. Microalbuminuria: Definition, detection, and clinical significance. J Clin Hypertens (Greenwich) 2004;6 11 Suppl 3:2-7.
43. Cho HM, Kim HC, Lee JM, Oh SM, Choi DP, Suh I. The association between serum albumin levels and metabolic syndrome in a rural population of Korea. J Prev Med Public Health 2012;45(2):98-104.
44. Moe OW, Pearle MS, Sakhaee K. Pharmacotherapy of urolithiasis: Evidence from clinical trials. Kidney Int 2011;79(4):385-92.
45. Wiederkehr MR, Moe OW. Uric acid nephrolithiasis: A systemic metabolic disorder. Clin Rev Bone Miner Metab 2011;9(3-4):207-17.
46. Sodimbaku LP. Urolithiasis - An updated review over genetics, pathophysiology and its clinical management. Int J Pharm Pharm Sci 2014;6(11):23-31.
47. Caraceni P, Tufoni M, Bonavita ME. Clinical use of albumin. Blood Transfus 2013;11 Suppl 4:s18-25.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.